



# BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017  
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com  
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)  
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 14<sup>th</sup> February 2022

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
---	--

Sub: Submission of Un-Audited Financial Result for the quarter and nine months ended on 31<sup>st</sup> December, 2021 together with Limited Review Report thereon.


BSE Code: 524396; NSE Script Code: BIOFILCHEM, ISIN No INE829A01014

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are hereby enclosing Un-Audited Financial Results together with Limited Review Report thereon for the quarter and nine months ended on 31<sup>st</sup> December, 2021 duly approved by the Board of Directors of the Company at its meeting held today i.e. Monday, 14<sup>th</sup> February, 2022. **Copy of Unaudited Financial Results is enclosed with this letter.**

Further, copy of Un-Audited Financial Statements shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid Results shall also be uploaded on website of Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and on the website of the Company at [www.biofilgroup.net](http://www.biofilgroup.net). The extract of aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper.

Yours Faithfully  
For Biofil Chemicals and Pharmaceuticals Limited



Ramesh Shah  
Chairman & Managing Director  
(DIN No. 00028819)

Encl: a/a

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2021**

Sr No.	Particulars	Quarter Ended			Nine Month Ended		Year Ended
		3 months ended on 31/12/2021	Previous 3 months ended on 30/09/2021	Corresponding 3 months ended on 31/12/2020	Year to date figures for Current period ended 31/12/2021	Year to date figures for Previous period ended 31/12/2020	Previous Year ended March 31 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operation	163.02	1373.79	319.20	2073.68	2151.17	3,575.04
II	Other Income	6.85	3.11	2.21	12.02	80.42	79.99
III	<b>Total Income (I + II)</b>	<b>169.87</b>	<b>1376.90</b>	<b>321.42</b>	<b>2085.70</b>	<b>2231.59</b>	<b>3655.04</b>
IV	<b>Expenses</b>						
	(a) Cost of materials consumed	39.95	90.65	276.19	186.45	554.79	685.12
	(b) Purchases of stock-in-trade	56.34	1251.29	2.18	1355.00	1287.53	2834.43
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(16.84)	(38.84)	-72.03	307.94	58.33	(276.86)
	(d) Employee benefits expense	17.72	19.94	23.66	55.07	63.67	75.16
	(e) Finance Cost	1.09	0.97	10.87	3.03	15.32	6.81
	(f) Depreciation and Amortisation Expense	10.30	10.30	1.16	30.89	22.25	41.19
	(g) Other Expenses						
	1. Manufacturing Expenses	10.60	8.54	17.32	26.93	38.89	55.57
	2. Administrative Expenses	5.42	3.62	4.05	19.93	16.46	32.46
	3. Selling and Distribution Expenses	1.25	1.37	6.77	3.26	8.74	9.26
	<b>Total expenses (IV)</b>	<b>125.83</b>	<b>1347.85</b>	<b>270.17</b>	<b>1988.52</b>	<b>2065.97</b>	<b>3463.14</b>
V	<b>Profit/ (Loss) before exceptional items and tax (III-IV)</b>	<b>44.04</b>	<b>29.05</b>	<b>51.25</b>	<b>97.19</b>	<b>165.63</b>	<b>191.90</b>
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit/ (Loss) before tax (V - VI)</b>	<b>44.04</b>	<b>29.05</b>	<b>51.25</b>	<b>97.19</b>	<b>165.63</b>	<b>191.90</b>
VIII	<b>Tax expense:</b>						
	(1) Current tax	10.00	7.79	0.00	24.49	0.00	32.75
	(2) Deferred tax Credit/(Charge)	0.00	0.00	0.00	0.00	0.00	35.01
IX	<b>Profit/(Loss) for the period from continuing operation (VII-VIII)</b>	<b>34.04</b>	<b>21.26</b>	<b>51.25</b>	<b>72.70</b>	<b>165.63</b>	<b>124.14</b>
X	Profit/(Loss) from dis-continued operation	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(Loss) from dis-continued operation after tax (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	<b>Profit/ (Loss) for the period (IX+XII)</b>	<b>34.04</b>	<b>21.26</b>	<b>51.25</b>	<b>72.70</b>	<b>165.63</b>	<b>124.14</b>
XIV	<b>Other Comprehensive Income</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.63
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	(0.18)
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
XV	<b>Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)</b>	<b>34.04</b>	<b>21.26</b>	<b>51.25</b>	<b>72.70</b>	<b>165.63</b>	<b>124.59</b>
XVI	<b>Paid-Up equity share capital (face value of Rs 10/- each)</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>
XVII	<b>Reserves (Excluding Revaluation Reserve)</b>						-390.50

XVIII	Earnings per equity shares (for continuing operation):						
	(1) Basic (Rs)	0.21	0.13	0.31	0.45	1.02	0.77
	(2) Diluted (Rs)	0.21	0.13	0.31	0.45	1.02	0.77
XIX	Earnings Per Equity Share (for discontinued operation)						
	(1) Basic (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
XX	Earnings Per Equity Share (for continuing & discontinued operation)						
	(1) Basic (Rs)	0.21	0.13	0.31	0.45	1.02	0.77
	(2) Diluted (Rs)	0.21	0.13	0.31	0.45	1.02	0.77

- 1 The above unaudited financial results for the Quarter and nine month ended dec. 31, 2021 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in it's meeting held on February 14, 2022. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
  - a. Pharma Division
  - b. Chemicals Division.
- 4 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 5 The aforesaid un-audited financial Results will be uploaded on the Company's website [www.biofilgroup.net](http://www.biofilgroup.net) and will also be available on the websites of the Stock exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) for the benefit of shareholders and investors.

Date : 14-02-2022  
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.



RAMESH SHAH  
CHAIRMAN & MANAGING DIRECTOR  
(DIN: 00028819)



## Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718,


### SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR QUARTER AND NINE MONTH ENDED 31ST DECEMBER, 2021

S.No.	Segment Revenue	( Amount in Lakhs)					
		Quarter Ended			Nine Month Ended		Year Ended
		3 Month Ended 31/12/2021	Preceeding 3 Month Ended 30/09/2021	Corresponding 3 months ended in the previous year (31/12/2020)	Year to date figures for current period ended (31/12/2021)	Year to date figures for the previous year ended (31/12/2020)	Previous Year ended March 31 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	Pharma Unit	106.60	1,305.46	77.32	1,880.11	1,486.68	2,700.01
	Chemicals Division	56.42	68.33	241.88	193.58	664.49	875.03
	Other	6.85	3.11	2.21	12.02	80.42	80.45
	Gross Turnover	169.87	1,376.90	321.42	2,085.70	2,231.59	3,655.49
2	Segment Results						
	Pharma Unit	40.56	41.77	48.43	109.76	102.70	117.25
	Chemicals Division	4.04	-12.27	3.99	-11.12	68.51	79.41
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total Segment Profit Before Tax & Interest	44.61	29.50	52.42	98.64	171.22	196.66
	Interest Income	0.53	0.53	0.00	1.58	0.00	2.11
	Finance Cost	1.09	0.97	1.16	3.03	5.60	6.42
	Other Unallocable Income net of Expenditure						
	Profit Before Tax	44.04	29.05	51.25	97.19	165.62	192.35
	current tax	10.00	7.79	0.00	24.49	0.00	32.75
	Deferred Tax	0.00	0.00	0.00	0.00	0.00	35.01
	Profit After Tax	34.04	21.26	51.25	72.70	165.62	124.59
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	2,528.41	2,134.75	681.72	2,528.41	681.72	2,158.34
	Chemicals Division	1,196.39	1,217.26	1292.01	1,196.39	1,292.01	1,165.50
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total (A)	3,724.80	3,352.01	1,973.73	3,724.80	1,973.73	3,323.84
	Segment Liabilities (B)						
	Pharma Division	1,564.25	1,567.44	71.19	1,564.25	71.19	1,615.99
	Chemicals Division	464.95	118.35	252.06	464.95	252.06	94.77
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total (B)	2,029.20	1,685.78	323.25	2,029.20	323.25	1,710.76
	Total Capital Employed (Segment Assets-Segment Liabilities)						
	Pharma Division	964.16	567.32	610.53	964.16	610.53	542.35
	Chemicals Division	731.44	1,098.91	1,039.95	731.44	1,039.95	1,070.73
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	1,695.60	1,666.23	1,650.48	1,695.60	1,650.48	1,613.09

Date : 14-02-2022

Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

  
RAMESH SHAH  
CHAIRMAN & MANAGING DIRECTOR  
( DIN: 00028819)






**Independent Auditor's Review Report on the Quarterly Unaudited and Year to Date Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read with SEBI Circular No. CIRJCFD/CMDI/44/2019 dated March 29, 2019**

To,  
The Board of Directors  
Biofil Chemicals and Pharmaceuticals Limited  
Indore (M.P.)

We have reviewed the accompanying statement of unaudited Standalone Financial results ("the statement") of **Biofil Chemicals and Pharmaceuticals Limited** ("**the company**") for the quarter ended ended 31st December, 2021 and year to date from 01<sup>st</sup> April, 2021 to 31st December, 2021. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI(Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures, A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be





aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MAHESHWARI & GUPTA**  
Chartered Accountants  
FRN: 006179C

  
CA. SUNIL MAHESHWARI  
Partner  
M. No. 403346

PLACE : INDORE

DATE : 14/02/2022

UDIN : 22403346 ACA WC I3888